Whether HIV patients had hepatitis or not didn't change the benefit of visceral fat loss on liver enzymes when taking tesamorelin.

Whether people with HIV had hepatitis or not didn't change the relationship between losing belly fat and improving liver enzymes.

Whether HIV patients had hepatitis or not didn't change the link between losing visceral fat and improving liver enzyme levels.

When belly fat decreases in people with HIV, liver fat also tends to decrease, showing a connection between these two types of fat.

For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from tesamorelin treatment had much bigger drops in their liver enzyme levels compared to those who didn't lose much fat.

HIV patients with high liver enzymes who lost enough belly fat from tesamorelin were more than twice as likely to have their ALT levels return to normal compared to those who didn't lose much fat.